28/03/2026
Cholangiocarcinoma remains a challenging cancer to diagnose and treat — with many patients presenting at an advanced stage.
But with up to 40–50% of patients harbouring actionable mutations, earlier molecular testing is becoming increasingly important in shaping treatment pathways.
In our latest podcast episodes, Rachael Babin is joined by Professor Morteza Aghmesheh and Dr Chris Rogan to explore:
• Why early molecular profiling matters
• The role of multidisciplinary care
• Practical challenges in tissue acquisition
• How interventional radiology is expanding treatment options
A really insightful discussion on how better coordination — and earlier testing — could open up more opportunities for patients.
🎧 Listen here: https://oncologynetwork.com.au/the-multidisciplinary-management-of-cholangiocarcinoma/
